To investigate if this molecularly enhanced progestin therapy can be applied to advanced endometrial cancer patients with ERα and PR negative tumors; we generated ERα null endometrial cancer cell lines by applying novel CRISPR-Cas9 technology to delete ERα at the genomic level (ESR1). Here, ESR1 is linked to endometrial cancer.